Vanderbilt Basic Sciences
-
Collaborative research lays groundwork for potential treatment of a rare and deadly type of cancer
A collaborative project between the labs of William Tansey, Ingram Professor of Cancer Research and professor of cell and developmental biology and biochemistry, and Stephen Fesik, Orrin H. Ingram II Chair in Cancer Research and professor of biochemistry, chemistry and pharmacology, has… Read MoreApr. 25, 2022
-
Prothena and Warren Center for Neuroscience Drug Discovery collaborate on new Alzheimer’s disease therapeutics
Prothena and the Warren Center for Neuroscience Drug Discovery have entered into a collaborative research agreement to develop new small molecule therapeutics for the treatment of Alzheimer’s disease in individuals with Down syndrome. Down syndrome is a condition in which a person’s having… Read MoreApr. 22, 2022
-
Attend ‘Survivor: Intersections of Cancer and Mental Health with Ethan Zohn’ on April 26
Ethan Zohn, winner of the CBS reality show Survivor, two-time cancer survivor, humanitarian and former professional soccer player, will discuss his journey with reality television, cancer, mental health and humanitarian work as part of the School of Medicine Basic Sciences’ monthly Lab-to-Table Conversations on Tuesday, April… Read MoreApr. 8, 2022
-
Study advances understanding of bacterial bioterrorism agent
Vanderbilt researchers have identified a critical regulatory factor in Bacillus anthracis, the bacterium that causes the disease anthrax and has been used as a biological weapon. The findings, reported in the journal Nature Communications, provide new insights into bacterial gene regulation and may guide novel antibacterial therapeutic… Read MoreApr. 8, 2022
-
New prognosis predictor and target for gastric cancer
Treatment resistance is especially pronounced in gastric cancer and contributes to patient mortality, highlighting the need for resensitization strategies. Robert Coffey, MD, Xiaodi Zhao, PhD, and colleagues compared the secretome, or secreted proteins, of chemoresistant and chemosensitive human gastric cancer cell lines to identify biomarkers of resistance. Read MoreApr. 8, 2022
-
Vanderbilt University, Medical Center reach $1B milestone together in research funding
Scholars at Vanderbilt University and Vanderbilt University Medical Center achieved a significant milestone in 2021: more than $1 billion in research funding awarded from external organizations. Vanderbilt’s global leadership in research—from biomedical and biotechnology discoveries to vaccine development to groundbreaking advances in computer science, education and psychology—contributed to this landmark… Read MoreApr. 5, 2022
-
WCNDD-developed Parkinson’s drug to enter next phase of clinical trial
A drug aimed at improving the lives of patients living with Parkinson’s disease will go to the next phase of clinical trials, thanks to a $13.5 million investment raised by Nashville’s Appello Pharmaceuticals. The clinical-stage pharmaceutical company that focuses on nervous system disorders announced Tuesday that its lead drug,… Read MoreApr. 4, 2022
-
Biologists discover signaling pathways potentially associated with pancreatic cancer
Kathleen DelGiorno, assistant professor of cell and developmental biology, her lab and collaborators at the Salk Institute have discovered some of the specific signaling molecules involved in tumor progression in pancreatic cancer. These molecules, called eicosanoids, play a role in inflammation and… Read MoreApr. 1, 2022
-
Vanderbilt ranks 12th in annual survey of NIH funding; 2021 awards topped $445M
Vanderbilt University again ranked among the nation’s top research institutions receiving funding from the National Institutes of Health, according to the latest data compiled by the Blue Ridge Institute for Medical Research. The total amount Vanderbilt scholars received across the School of… Read MoreApr. 1, 2022
-
Crowe receives national award for COVID antibody research
James Crowe Jr., MD, director of the Vanderbilt Vaccine Center, and Michel Nussenzweig, MD, PhD, of The Rockefeller University, have been jointly awarded the 2022 Harrington Prize for Innovation in Medicine for “groundbreaking work” that enabled the use of human antibodies to treat COVID-19. The announcement was made… Read MoreApr. 1, 2022